215 related articles for article (PubMed ID: 34018907)
1. Proposition of a new allosteric binding site for potential SARS-CoV-2 3CL protease inhibitors by utilizing molecular dynamics simulations and ensemble docking.
Novak J; Rimac H; Kandagalla S; Pathak P; Naumovich V; Grishina M; Potemkin V
J Biomol Struct Dyn; 2022; 40(19):9347-9360. PubMed ID: 34018907
[TBL] [Abstract][Full Text] [Related]
2. Pharmacoinformatics and molecular dynamics simulation studies reveal potential covalent and FDA-approved inhibitors of SARS-CoV-2 main protease 3CL
Alamri MA; Tahir Ul Qamar M; Mirza MU; Bhadane R; Alqahtani SM; Muneer I; Froeyen M; Salo-Ahen OMH
J Biomol Struct Dyn; 2021 Aug; 39(13):4936-4948. PubMed ID: 32579061
[TBL] [Abstract][Full Text] [Related]
3. Multidimensional virtual screening approaches combined with drug repurposing to identify potential covalent inhibitors of SARS-CoV-2 3CL protease.
Wang Y; Gao Q; Yao P; Yao Q; Zhang J
J Biomol Struct Dyn; 2023; 41(24):15262-15285. PubMed ID: 36961210
[TBL] [Abstract][Full Text] [Related]
4. Drug repurposing studies targeting SARS-CoV-2: an ensemble docking approach on drug target 3C-like protease (3CL
Koulgi S; Jani V; Uppuladinne M; Sonavane U; Nath AK; Darbari H; Joshi R
J Biomol Struct Dyn; 2021 Sep; 39(15):5735-5755. PubMed ID: 32679006
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of apigenin-based biflavonoid derivatives as potential therapeutic agents against viral protease (3CLpro) of SARS-CoV-2 via molecular docking, molecular dynamics and quantum mechanics studies.
Abdizadeh R; Hadizadeh F; Abdizadeh T
J Biomol Struct Dyn; 2023; 41(13):5915-5945. PubMed ID: 35848354
[TBL] [Abstract][Full Text] [Related]
6. QSAR, molecular docking, molecular dynamics and MM-GBSA approach for identification of prospective benzotriazole-based SARS-CoV 3CL protease inhibitors.
D'Souza S; Balaji S; K V P
J Biomol Struct Dyn; 2022; 40(24):14247-14261. PubMed ID: 34877897
[TBL] [Abstract][Full Text] [Related]
7. Chetomin, a SARS-CoV-2 3C-like Protease (3CL
Ibrahim MAA; Abdelrahman AHM; Mohamed DEM; Abdeljawaad KAA; Naeem MA; Gabr GA; Shawky AM; Soliman MES; Sidhom PA; Paré PW; Hegazy MF
Viruses; 2023 Jan; 15(1):. PubMed ID: 36680290
[TBL] [Abstract][Full Text] [Related]
8. Allosteric inhibitors of the main protease of SARS-CoV-2.
Samrat SK; Xu J; Xie X; Gianti E; Chen H; Zou J; Pattis JG; Elokely K; Lee H; Li Z; Klein ML; Shi PY; Zhou J; Li H
Antiviral Res; 2022 Sep; 205():105381. PubMed ID: 35835291
[TBL] [Abstract][Full Text] [Related]
9. Binding and inhibitory effect of ravidasvir on 3CL
Bera K
J Biomol Struct Dyn; 2022 Oct; 40(16):7303-7310. PubMed ID: 33682639
[TBL] [Abstract][Full Text] [Related]
10. Virtual screening of approved clinic drugs with main protease (3CL
Wang Q; Zhao Y; Chen X; Hong A
J Biomol Struct Dyn; 2022 Feb; 40(2):685-695. PubMed ID: 32909528
[TBL] [Abstract][Full Text] [Related]
11. Elucidation of the inhibitory activity of plant-derived SARS-CoV inhibitors and their potential as SARS-CoV-2 inhibitors.
Bello M; Hasan MK
J Biomol Struct Dyn; 2022; 40(20):9992-10004. PubMed ID: 34121618
[TBL] [Abstract][Full Text] [Related]
12. Finding potent inhibitors for COVID-19 main protease (M
Motiwale M; Yadav NS; Kumar S; Kushwaha T; Choudhir G; Sharma S; Singour PK
J Biomol Struct Dyn; 2022 Mar; 40(4):1534-1545. PubMed ID: 33030102
[TBL] [Abstract][Full Text] [Related]
13. Identifying the natural compound Catechin from tropical mangrove plants as a potential lead candidate against 3CL
Jha RK; Khan RJ; Parthiban A; Singh E; Jain M; Amera GM; Singh RP; Ramachandran P; Ramachandran R; Sachithanandam V; Muthukumaran J; Singh AK
J Biomol Struct Dyn; 2022; 40(24):13392-13411. PubMed ID: 34644249
[TBL] [Abstract][Full Text] [Related]
14. Identification of a novel dual-target scaffold for 3CLpro and RdRp proteins of SARS-CoV-2 using 3D-similarity search, molecular docking, molecular dynamics and ADMET evaluation.
Aouidate A; Ghaleb A; Chtita S; Aarjane M; Ousaa A; Maghat H; Sbai A; Choukrad M; Bouachrine M; Lakhlifi T
J Biomol Struct Dyn; 2021 Aug; 39(12):4522-4535. PubMed ID: 32552534
[TBL] [Abstract][Full Text] [Related]
15. Targeting allosteric pockets of SARS-CoV-2 main protease M
Bhat ZA; Chitara D; Iqbal J; Sanjeev BS; Madhumalar A
J Biomol Struct Dyn; 2022 Sep; 40(14):6603-6618. PubMed ID: 33645457
[TBL] [Abstract][Full Text] [Related]
16. Molecular docking and simulation studies of synthetic protease inhibitors against COVID-19: a computational study.
Gouhar SA; Elshahid ZA
J Biomol Struct Dyn; 2022; 40(24):13976-13996. PubMed ID: 34738871
[TBL] [Abstract][Full Text] [Related]
17. Possibility of HIV-1 protease inhibitors-clinical trial drugs as repurposed drugs for SARS-CoV-2 main protease: a molecular docking, molecular dynamics and binding free energy simulation study.
Ancy I; Sivanandam M; Kumaradhas P
J Biomol Struct Dyn; 2021 Sep; 39(15):5368-5375. PubMed ID: 32627689
[TBL] [Abstract][Full Text] [Related]
18.
Iype E; Pillai U J; Kumar I; Gaastra-Nedea SV; Subramanian R; Saha RN; Dutta M
J Biomol Struct Dyn; 2022; 40(23):12800-12811. PubMed ID: 34550861
[TBL] [Abstract][Full Text] [Related]
19. Identification of structural scaffold from interbioscreen (IBS) database to inhibit 3CLpro, PLpro, and RdRp of SARS-CoV-2 using molecular docking and dynamic simulation studies.
Patil VR; Dhote AM; Patil R; Amnerkar ND; Lokwani DK; Ugale VG; Charbe NB; Firke SD; Chaudhari P; Shah SK; Mehta CH; Nayak UY; Khadse SC
J Biomol Struct Dyn; 2023; 41(22):13168-13179. PubMed ID: 36757134
[TBL] [Abstract][Full Text] [Related]
20. Finding potent inhibitors against SARS-CoV-2 main protease through virtual screening, ADMET, and molecular dynamics simulation studies.
Roy R; Sk MF; Jonniya NA; Poddar S; Kar P
J Biomol Struct Dyn; 2022 Sep; 40(14):6556-6568. PubMed ID: 33682642
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
